Lipid nanoparticle-encapsulated microRNA-192: An anti-inflammatory adjuvant that enhances vaccine efficacy in aged...

Area of Science:

• Immunology
• Gerontology
• Molecular Biology

Background:

• Chronic inflammation, often exacerbated by aging, impairs immune function and reduces vaccine effectiveness.
• Proinflammatory cytokines like IL-6 and TNF-α at vaccination sites can suppress antibody production.
• Aging-related inflammation creates a hostile environment for optimal vaccine responses.

Purpose of the Study:

• To develop lipid nanoparticles (LNPs) encapsulating anti-inflammatory microRNA-192 (miR-192).
• To evaluate the potential of miR-192 loaded LNPs to attenuate inflammation and improve vaccine efficacy in aged individuals.
• To investigate the molecular mechanisms by which miR-192 influences inflammatory pathways and vaccine responses.

Main Methods:

• Development of lipid nanoparticles (LNPs) encapsulating microRNA-192 (miR-192).
• Administration of miR-192 LNPs in aged mouse models to assess anti-inflammatory effects and vaccine efficacy.
• Measurement of proinflammatory cytokine levels (IL-6, TNF-α) at vaccination sites.
• Transcriptomic analysis to identify downregulated genes and affected signaling pathways (e.g., JAK-STAT).
• Assessment of antigen-specific antibody production.

Main Results:

• miR-192 loaded LNPs demonstrated significant anti-inflammatory properties.
• Vaccine efficacy was markedly enhanced in aged mice treated with miR-192 LNPs.
• miR-192 downregulated key pro-inflammatory cytokines, including senescence-associated secreted phenotype factors.
• The JAK-STAT signaling pathway, critical for myeloid cell cytokine signaling, was inhibited by miR-192.
• Reduced levels of IL-6 and TNF-α correlated with improved antibody production.

Conclusions:

• miR-192 effectively suppresses detrimental inflammatory responses associated with aging.
• miR-192 loaded LNPs show significant therapeutic potential for enhancing vaccine efficacy in the elderly.
• MicroRNA-based adjuvants represent a promising strategy to overcome age-related declines in immunity and vaccination outcomes.